Nuclear medicine is concept-dense and rewards focused revision — PET-CT, radiotracers, and theranostics recur in NEET SS and INI-SS. These free samples from the RadioQBank published set come with full explanations, exam pearls, and references.
Question 1 · Thyroid Scan · easy
A Tc-99m pertechnetate thyroid scan in a 35-year-old woman with hyperthyroidism shows diffusely enlarged thyroid with homogeneously increased uptake in both lobes. The 24-hour radioiodine uptake (RAIU) is 72%. Which diagnosis does this scan pattern most support?
- a. Toxic multinodular goitre
- b. Graves disease
- c. Subacute (De Quervain) thyroiditis
- d. Solitary toxic adenoma
Answer: B. Graves disease is an autoimmune condition in which TSH receptor antibodies (TRAb) mimic TSH, causing diffuse thyroid hyperplasia and autonomous stimulation. On thyroid scintigraphy, this produces a diffusely enlarged gland with homogeneously increased uptake throughout both lobes — the classic Graves pattern. RAIU is markedly elevated (typically >50%) because the entire gland is uniformly overstimulated. This distinguishes it from toxic multinodular goitre (patchy uptake with suppressed background) and from solitary adenoma (single hot nodule with suppressed remainder).
Exam pearl: Graves disease = diffuse homogeneous uptake + elevated RAIU; subacute thyroiditis = suppressed uptake + low RAIU.
Grainger & Allison's Diagnostic Radiology 7th ed, Chapter 73; AJR 2012;199:1170–1179
Question 2 · Theranostics — PSMA · easy
A 72-year-old man with castration-resistant prostate cancer (CRPC) and PSA 45 ng/mL undergoes 177Lu-PSMA-617 therapy. Which pre-treatment scan is MANDATORY to confirm target expression before therapy?
- a. 18F-FDG PET/CT
- b. 99mTc-MDP bone scan
- c. 68Ga-PSMA-11 or 18F-DCFPyL PET/CT
- d. 68Ga-DOTATATE PET/CT
Answer: C. 177Lu-PSMA-617 is a theranostic agent — the therapeutic lutetium-177 counterpart to the diagnostic 68Ga-PSMA tracer. The VISION trial (NEJM 2021) established that patients must demonstrate PSMA-positive disease (all metastatic lesions PSMA-avid exceeding liver background, with no PSMA-negative metastases on FDG) on pre-treatment 68Ga-PSMA-11 or 18F-DCFPyL PET/CT. This theranostic pair principle ensures the therapeutic agent reaches the target.
Exam pearl: Theranostic pair: 68Ga-PSMA (diagnose) + 177Lu-PSMA-617 (treat) — VISION trial mandates pre-therapy PSMA PET to confirm target expression before 177Lu therapy.
Sartor O et al. NEJM 2021 (VISION trial); J Nucl Med 2022
Question 3 · PET-CT Neurology · hard
A cognitively impaired adult being evaluated for Alzheimer disease has flortaucipir PET retention limited to mesial temporal structures, without the neocortical pattern required for a positive clinical read. Which conclusion is most appropriate?
- a. It cannot exclude early tau pathology or assign an exact early Braak stage
- b. The pattern establishes advanced neocortical Braak V–VI disease
- c. The pattern by itself establishes Alzheimer dementia
- d. The pattern excludes clinically relevant underlying tau pathology
Answer: A. Isolated mesial-temporal retention does not establish an exact early Braak stage or a clinical AD diagnosis. Approved flortaucipir visual positivity is based on a neocortical pattern; a negative scan may still coexist with earlier tau pathology.
Exam pearl: A negative clinical flortaucipir scan does not exclude early tau pathology.
TAUVID prescribing information 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212123s031lbl.pdf
Question 4 · PET-CT Cardiac · hard
In a research PET study of calcific aortic stenosis, increased 18F-NaF uptake is present in the aortic valve. Which mechanism does the tracer primarily reflect?
- a. Active mineral deposition at hydroxyapatite surfaces
- b. Myocardial perfusion through first-pass tracer extraction
- c. Direct binding to amyloid fibrils
- d. Glucose utilisation proportional to myocardial workload
Answer: A. Fluoride binds at mineralisation sites through exchange at hydroxyapatite. In aortic-valve research imaging, increased uptake reflects active calcification. It is not a perfusion tracer or a direct measure of myocardial fibrotic tissue.
Exam pearl: Cardiovascular NaF uptake reflects active calcification rather than directly measuring fibrosis.
SNMMI/ASNC/EANM cardiovascular hot-spot imaging statement: https://jnm.snmjournals.org/content/63/11/1722; Dynamic bone imaging: diphosphonates and fluoride: https://jnm.snmjournals.org/content/54/4/590